Clinical Trial Update: A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing Tacrolimus (Prograf) with Prograf-XL in de novo kidney transplant recipients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Transplantation

Drugs mentioned

• Prograf (Tacrolimus)
• Prograf-XL (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Kidney Transplantation, Transplantation Immunology | Phase 3 | Status: COMPLETED